Company / Cash & Equivalents
Ceribell, Inc. Cash & Equivalents History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$40.5M
FY2025
5-year range
$34.5M / $194.4M
FY2023-FY2025
Trend
-79.2%
vs FY2024
Sector context
#133 of 148
Health Care
What the data says
Among 148 Health Care companies, Ceribell, Inc. is in the bottom 10% for cash & equivalents. Improved from $34M to $40M over the past 2 years.
Based on SEC 10-K filings.
$40M in FY2025.
Improved from $34M to $40M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 10% in Health CareTop 90% of 148This company $40.5M Sector average $1.2B
▼
-96.6% below sector average
Key checks
Key Insights
- In FY2025, cash & equivalents decreased 79.2% year-over-year.
- Ranks #133 out of 148 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.80 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $40.5M | -79.2% |
| FY2024 | $194.4M | +463.5% |
| FY2023 | $34.5M | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026